Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Gritstone bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GRTS
Nasdaq
8731
https://gritstonebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Gritstone bio Inc
3 Speculative Stocks You Can Buy for $3 or Less
- Mar 19th, 2024 6:49 pm
Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates
- Mar 8th, 2024 10:17 am
Gritstone bio Full Year 2023 Earnings: Beats Expectations
- Mar 7th, 2024 10:14 am
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Mar 5th, 2024 9:05 pm
Gritstone bio Announces Workforce Reduction
- Feb 29th, 2024 9:05 pm
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
- Feb 21st, 2024 12:00 pm
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
- Feb 12th, 2024 12:00 pm
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 8th, 2024 9:30 pm
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
- Jan 31st, 2024 9:00 pm
Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago
- Jan 23rd, 2024 10:19 am
Gritstone bio to Participate in Upcoming Investor Conference
- Jan 17th, 2024 12:00 pm
Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved Drastically
- Dec 13th, 2023 10:05 am
Gritstone bio to Participate in Upcoming Investor Conferences
- Nov 20th, 2023 12:00 pm
Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine Development
- Nov 8th, 2023 11:43 pm
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Nov 8th, 2023 9:05 pm
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
- Oct 12th, 2023 9:00 pm
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Oct 11th, 2023 11:10 am
retail investors who own 43% along with institutions invested in Gritstone bio, Inc. (NASDAQ:GRTS) saw increase in their holdings value last week
- Oct 5th, 2023 11:49 am
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
- Oct 4th, 2023 8:05 pm
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
- Sep 27th, 2023 8:01 pm
Scroll